Rina-S + Standard of Care for Ovarian Cancer

(RAINFOL-04 Trial)

This trial explores the effectiveness of a new treatment, Rina-S, against ovarian cancer when combined with standard care. Participants will receive either Rina-S alone, Rina-S with bevacizumab (a current treatment), or just bevacizumab. The goal is to determine if Rina-S can manage the cancer more effectively. The trial seeks individuals with ovarian cancer who have undergone specific chemotherapy treatments and whose cancer has not worsened recently. Participants will visit the clinic regularly for tests and monitoring to ensure the treatment's safety and effectiveness. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify if you need to stop taking your current medications. However, it mentions that participants should not receive any other systemic anticancer treatment (except bevacizumab) after their last dose of second-line platinum-based chemotherapy and before joining the trial.

Research has shown that Rina-S is generally well-tolerated by patients. Earlier studies found that the side effects of Rina-S were manageable, with no new safety issues identified. While some side effects might occur, they are usually not serious and can be controlled. Rina-S has been tested in people with various types of solid tumors, providing a better understanding of its safety. Individual experiences may vary, and the study team will closely monitor participants for any side effects.¹²³⁴⁵

Unlike the standard treatments for ovarian cancer, which typically include chemotherapy and bevacizumab, Rina-S is being tested for its potential to enhance the efficacy of these existing therapies. Researchers are excited about Rina-S because it may offer a novel mechanism of action that targets cancer cells more precisely. This could potentially improve outcomes by reducing tumor growth and delaying progression, providing new hope for patients.

Research has shown that Rina-S, which participants in this trial may receive, holds promise for treating ovarian cancer. In one study, 55.6% of patients experienced tumor shrinkage with Rina-S. Another study found that up to 88.9% of patients had either tumor shrinkage or stability. These findings suggest that Rina-S could effectively manage ovarian cancer, especially when combined with standard treatments like bevacizumab, which is part of the standard care in this trial.¹²⁵⁶⁷